66-02-4

Usage

Uses

3,5-Diiodo-DL-tyrosine is used for diagnosis of hypothyroidism caused by DEHAL1 gene defects.

InChI:InChI=1/C9H9I2NO3/c10-5-1-4(2-6(11)8(5)13)3-7(12)9(14)15/h1-2,7,13H,3,12H2,(H,14,15)

Upstream product

• 556-02-5 ?Tyr 
• 3078-39-5 3-iodo-DL-tyrosine 
• 60-18-4 L-tyrosine 
• 7553-56-2 iodine 

Downstream Products

• 23239-20-5 2-Amino-3-(4-hydroxy-3,5-diiodo-phenyl)-propionic acid methyl ester; hydrochloride 
• 556-02-5 ?Tyr 
• 7553-56-2 iodine 
• 52815-36-8 2,2,3,3,4,4,4-Heptafluoro-butyric acid 4-[2-(2,2,3,3,4,4,4-heptafluoro-butyrylamino)-2-methoxycarbonyl-ethyl]-2,6-diiodo-phenyl ester 
• 105245-15-6 N-acryloyl acryloyloxy-4 diiodo-3,5-L-phenylalanine 
• 105245-16-7 N-methacryloyl methacryloyloxy-4 diiodo-3,5-L-phenylalanine 
• 105245-18-9 N-methacryloyl diiodo-3,5-L-tyrosine 
• 105245-17-8 N-acryloyl diiodo-3,5-L-tyrosine 
• 49553-16-4 {Cu(HOC₆H₂I₂CH₂CH(NH₂)COO)2} 
• 765952-45-2 methyl 2-tert-butoxycarbonyl-6,8-diiodo-7-phenylethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 765952-48-5 ethyl 3-methoxycarbonyl-7-phenylethyl-1,2,3,4-tetrahydroisoquinoline-2-ethanoate 
• 765952-46-3 methyl 2-tert-butoxycarbonyl-7-phenylethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 765952-47-4 7-phenylethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 765952-42-9 methyl 7-phenylethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 

Relevant academic research and scientific papers

Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents

Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145 cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising in vitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.

Composition of matter having bioactive properties

Particles of coordinated complex comprising a basic, hydrous polymer and a capacitance adding compound, as well as methods for their production, are described. These complexes exhibit a high degree of bioactivity making them suitable for a broad range of applications through their incorporation into conventional vehicles benefiting from antimicrobial and similar properties.

Regioselective iodination of tyrosine in a liquid membrane system, in the presence of crown ether type macrocyclic ligands. I obtention of monoiodotyrosine

The experiments performed have shown that, when using a "liquid membrane" system (aqueous phase source containing KI + I2 K+I3-, the receiving aqueous phase containing tyrosine, the "liquid membrane" being represented by dichloroethane, which contains the crown ether CE =18-crown-6), the selective iodination of tyrosine can be controlled so as to obtain, after four hours, monoiodotyrosine with a 100% yield.

Regioselective iodination of tyrosine in a liquid membrane system in the presence of crown ether type, macrocyclic ligands. II: The factors which influence regioselective iodination

The regioselective iodination of tyrosine 1 in a "liquid membrane" system - aqueous phase source/dichloroethane/aqueous receiving phase - in view of obtaining preferentially, first, monoiododerivative 2 and then diiododerivative 3 is controlled by the exclusive existence in the "liquid membrane" of the complex species [CE?I]+I3- (with no free I2). The highest yield (100%) of derivative 2 is obtained when CE=18-crown-6. The process is considered to be of the electophilic aromatic substitution type (through "phase transfer catalysis") the experiments suggesting that the reactive iodine species results from the [CE?I]+I3- complex decomposition at the "membrane"/receiving aqueous phase (containing tyrosine) interface.